These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 20151845

  • 1. Emerging MEK inhibitors.
    McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):203-23. PubMed ID: 20151845
    [Abstract] [Full Text] [Related]

  • 2. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
    McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, Steelman LS.
    Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
    [Abstract] [Full Text] [Related]

  • 3. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ, Der CJ.
    Oncogene; 2007 May 14; 26(22):3291-310. PubMed ID: 17496923
    [Abstract] [Full Text] [Related]

  • 4. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 14; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 5. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 14; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 6. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 14; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 7. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R, Piperdi S, Gorlick R.
    Clin Cancer Res; 2008 Oct 15; 14(20):6396-404. PubMed ID: 18927278
    [Abstract] [Full Text] [Related]

  • 8. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
    Friday BB, Adjei AA.
    Clin Cancer Res; 2008 Jan 15; 14(2):342-6. PubMed ID: 18223206
    [Abstract] [Full Text] [Related]

  • 9. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C, Settleman J.
    Cancer Lett; 2009 Oct 08; 283(2):125-34. PubMed ID: 19217204
    [Abstract] [Full Text] [Related]

  • 10. Novel targets in solid tumors: MEK inhibitors.
    Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG.
    Clin Adv Hematol Oncol; 2006 Nov 08; 4(11):831-6. PubMed ID: 17143253
    [Abstract] [Full Text] [Related]

  • 11. Emerging Raf inhibitors.
    McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.
    Expert Opin Emerg Drugs; 2009 Dec 08; 14(4):633-48. PubMed ID: 19715444
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 13. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).
    Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA.
    Int J Oncol; 2003 Mar 15; 22(3):469-80. PubMed ID: 12579299
    [Abstract] [Full Text] [Related]

  • 14. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells.
    Cheung HW, Ling MT, Tsao SW, Wong YC, Wang X.
    Carcinogenesis; 2004 Jun 15; 25(6):881-7. PubMed ID: 14742319
    [Abstract] [Full Text] [Related]

  • 15. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J.
    Expert Opin Investig Drugs; 2010 May 15; 19(5):605-14. PubMed ID: 20367532
    [Abstract] [Full Text] [Related]

  • 16. Targeting Raf/MEK/ERK pathway in pituitary adenomas.
    Suojun Z, Feng W, Dongsheng G, Ting L.
    Eur J Cancer; 2012 Feb 15; 48(3):389-95. PubMed ID: 22119203
    [Abstract] [Full Text] [Related]

  • 17. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV, Robertson GP.
    Cancer Res; 2008 Jan 01; 68(1):5-8. PubMed ID: 18172288
    [Abstract] [Full Text] [Related]

  • 18. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb 01; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

  • 19. Tyrosine kinase inhibitors to treat liver cancer.
    Huynh H.
    Expert Opin Emerg Drugs; 2010 Mar 01; 15(1):13-26. PubMed ID: 20128706
    [Abstract] [Full Text] [Related]

  • 20. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S, Djelloul S, Raymond E.
    Semin Oncol; 2006 Aug 01; 33(4):407-20. PubMed ID: 16890796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.